Skip to main content

Table 1 Patient characteristics and outcomes

From: Phase I study of low-dose metronomic temozolomide for recurrent malignant gliomas

No Adjuvant TMZ cycles mTMZ cycles Histology KPS score Metronomic dosage (mg/m2/d) Diagnosis to first recurrence (months) Progression free survival (months) Overall survival (months)
1 1 2 Glioblastoma 70 50 2.9 3.1 71.0
2 0 0 Glioblastoma 90 25 2.4 N/A 11.0
3 1 2 Small cell anaplastic astrocytoma 70 25 2.7 7.1 7.1
4 20 1 Glioblastoma 70 25 23.3 1.5 9.7
5 2 6 Glioblastoma 70 50 5.8 9.9 12.7
6 0 19 Anaplastic ogliodendroglioma 90 25 128.6 >107 Alive
7 13 1 Glioblastoma 70 50 18.1 1.9 12.6
8 1 5 Glioblastoma 60 50 3.6 11.4 14.4
9 0 8 Anaplastic glioma 70 50 120.0 22.9 33.7
  1. Baseline characteristics and outcomes among subjects treated with mTMZ